BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib-Reference-Cited by-同舟云学术

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib

Published:2021-03 Issue:3 Volume:2 Page:100113
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Karachaliou Niki,Arrieta Oscar,Giménez-Capitán Ana,Aldeguer Erika,Drozdowskyj Ana,Chaib Imane,Reguart Noemí,Garcia-Campelo Rosario,Chen Jing-Hua,Molina-Vila Miguel Angel,Rosell Rafael

Funder

“la Caixa” Foundation

Instituto de Salud Carlos III

H2020 Marie Skłodowska-Curie Actions

Fundación Científica Asociación Española Contra el Cáncer

Publisher

Elsevier BV

Reference24 articles.

1. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N Engl J Med,2009

2. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations;Rosell;Clin Cancer Res,2011

3. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130;Hegan;Proc Natl Acad Sci U S A,2010

4. Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL);Campelo;J Clin Oncol,2014

5. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): a multicenter, randomized phase II study (GOAL);García-Campelo;Lung Cancer,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer;Cancers;2024-06-12

2. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review;Translational Lung Cancer Research;2024-02

3. Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers;OncoTargets and Therapy;2023-07

4. Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy;Molecules;2022-07-25

5. Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report;Anti-Cancer Drugs;2022-03-23